Kooij Louise Frederika's Form 4 filing
NewAmsterdam Pharma Co N.V. (NAMS) · filed Dec 29, 2025
- Accession no.
- 0001193125-25-335513
- Filed
- Dec 29, 2025
- Trade date
- Dec 23-26, 2025
- Filing delay
- 6 days
- Rule 10b5-1 plan
- Checked
This filing lists 7 non-derivative transactions and 4 derivative transactions. Open-market sales total $5.20M. It was filed 6 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kooij Louise FrederikaCIK 0002004379 | Officer (Chief Accounting Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 23, 2025 | Ordinary Shares | MOption exerciseAcquired | +75,117 | $10.00 | +$751,170 | 90,117 | Direct | |
| Dec 23, 2025 | Ordinary Shares | SSaleDisposed | −75,117 | $36.21F1 | −$2,719,986.57 | 15,000 | Direct | |
| Dec 24, 2025 | Ordinary Shares | MOption exerciseAcquired | +26,011 | $10.00 | +$260,110 | 41,011 | Direct | |
| Dec 24, 2025 | Ordinary Shares | SSaleDisposed | −26,011 | $35.68F2 | −$928,072.48 | 15,000 | Direct | |
| Dec 26, 2025 | Ordinary Shares | MOption exerciseAcquired | +38,872 | $10.00 | +$388,720 | 53,872 | Direct | |
| Dec 26, 2025 | Ordinary Shares | MOption exerciseAcquired | +5,000 | $10.90 | +$54,500 | 58,872 | Direct | |
| Dec 26, 2025 | Ordinary Shares | SSaleDisposed | −43,872 | $35.30F3 | −$1,548,681.6 | 15,000 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 23, 2025 | Ordinary Shares | MOption exerciseDisposed | −75,117 | $0.00 | $0 | 204,898 | Direct | |
| Dec 24, 2025 | Ordinary Shares | MOption exerciseDisposed | −26,011 | $0.00 | $0 | 178,887 | Direct | |
| Dec 26, 2025 | Ordinary Shares | MOption exerciseDisposed | −38,872 | $0.00 | $0 | 140,015 | Direct | |
| Dec 26, 2025 | Ordinary Shares | MOption exerciseDisposed | −5,000 | $0.00 | $0 | 218,134 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.88 to $36.75 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
Referenced by the price of 1 transaction in Table I.
- F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.24 to $36.09 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.85 to $35.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
Referenced by the price of 1 transaction in Table I.